Monday, 31 August 2026European Markets

ATEME Stock 18.83% Up On Thursday

Loading stream...

(vianews) - the market ended the session with ateme (ateme.pa) rising 18.83% to €5.30 on thursday, following the last session's upward trend. cac 40 slid 0.02% to €8,151.55, following the last session's upward trend on what was a somewhat negative trend trading session today.

about ateme

ateme sa, together with its subsidiaries, provides electronic and computer devices and instruments worldwide. the company offers various solutions, such as titan live, a software-based live video compression for the converged headend; titan file, a video transcoding software; titan mux, a multi-function software stream processing solution; kyrion cm5000e, an ultra-low latency encoder; titan edge encoder; titan edge decoder; titan edge gateway; and kyrion dr5000, an ultra-low latency integrated receiver decoder. it also provides nea-cdn, an ott scale service solution; nea-dvr; nea-live for immersive viewing experience; nea-composer, a dynamic ad insertion and linear origination solution; pilot media, a cloud native media supply chain solution; and pilot manager, a cloud native management system. the company serves content providers, service providers, and streaming platforms. ateme sa was incorporated in 1991 and is headquartered in vélizy-villacoublay, france.

earnings per share

as for profitability, ateme has a trailing twelve months eps of €-0.28.

more news about ateme (ateme.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com